TRELEGY ELLIPTA
TRELEGY ELLIPTA
Approved
DIN Number
02474522
Drug Class
Human
Market Date
May 30, 2018
Company
HC
GlaxoSmithKline Inc
Product Information
Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.
Product Details
Health Canada regulatory and product classification information
Regulatory Identifiers
DIN Number02474522
AIG Number0360150001
Classification & Schedule
C
Drug Class
Human
S
Schedule
Prescription
A
ATC Code
R03AL08 VILANTEROL, UMECLIDINIUM BROMIDE AND FLUTICASONE FUROATE
Product Specifications
Dosage FormPowder
Route of AdministrationInhalation
AHFS Classification68:04.00
Health Canada Classification
ACTIVE INGREDIENTS (3)
FLUTICASONE FUROATEActive
Strength: 100 MCG / ACT
Monograph: FLUTICASONE FUROATE
UMECLIDINIUM (UMECLIDINIUM BROMIDE)Active
Strength: 62.5 MCG / ACT
Monograph: UMECLIDINIUM (UMECLIDINIUM BROMIDE)
VILANTEROL (VILANTEROL TRIFENATATE)Active
Strength: 25 MCG / ACT
Monograph: VILANTEROL (VILANTEROL TRIFENATATE)